U.S. FDA Requests Halt To CytRx Trial Of Lou Gehrig’s Disease Drug (India)
This article was originally published in PharmAsia News
The U.S. FDA has asked India's CytRx to stop its Phase II trial of a Lou Gehrig-disease drug because the company lacks the data to continue. The U.S. agency asked the company for more analysis of toxicology studies performed on animals for the arimoclomol drug aimed at treating amyotropic lateral sclerosis. CytRx said there was no data in any of the trials related to safety in humans, and the firm has asked for clarification. (Click here for more
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.